Non-aqueous colonic purgative formulations
    2.
    发明授权
    Non-aqueous colonic purgative formulations 失效
    非水结肠泻药配方

    公开(公告)号:US6162464A

    公开(公告)日:2000-12-19

    申请号:US829080

    申请日:1997-03-31

    摘要: Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg.sub.3 (PO.sub.4).sub.2, MgHPO.sub.4, Mg(H.sub.2 PO.sub.4).sub.2, MgSO.sub.4, MgCl.sub.2, Na.sub.2 SO.sub.4, sodium tartrate, potassium tartrate, magnesium tartrate and mixtures, thereof, administered in tablet or capsule form in purgative effective concentrations. Preferred embodiments make use of at least one or more magnesium phosphate salts, more preferably dibasic magnesium phosphate; other preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.

    摘要翻译: 口服施用的结肠泻药制剂及其用于在哺乳动物中部分或完全清除结肠的方法,所述制剂由选自Mg 3(PO 4)2,MgHPO 4,Mg( H 2 PO 4)2,MgSO 4,MgCl 2,Na 2 SO 4,酒石酸钠,酒石酸钾,酒石酸钾及其混合物,以片剂或胶囊形式以泻药有效浓度给药。 优选的实施方案使用至少一种或多种磷酸镁盐,更优选磷酸氢二钙; 其它优选的实施方案包括添加粘合剂,分散剂和缓冲液,其不会不利地影响泻药制剂的重量摩尔渗透压浓度或有效性。